<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362515</url>
  </required_header>
  <id_info>
    <org_study_id>17D.264</org_study_id>
    <nct_id>NCT03362515</nct_id>
  </id_info>
  <brief_title>Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide</brief_title>
  <official_title>Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior studies have suggested that topical furosemide may reduce the recurrence of sinonasal
      polyposis following sinus surgery. This project aims to further investigate that claim
      through a blinded randomized controlled clinical trial following patients who undergo
      functional sinus surgery for chronic rhinosinusitis with sinonasal polyposis by randomly
      assigning participants to receive topical furosemide versus placebo nasal spray for 2 months
      post operatively. Outcomes would be compared at 6 months through endoscopic grading scores
      using Lund Kennedy and Meltzer scores as well as Sino-Nasal Outcome Test (SNOT-22) scores to
      measure the rate and degree of recurrence and impact on symptoms in the treatment group
      versus placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polyp Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Nasal and paranasal polyposis based on endoscopic grading through Lund Kennedy score to measure the rate and degree of recurrence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polyp Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Nasal and paranasal polyposis based on endoscopic grading through Meltzer score to measure the rate and degree of recurrence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polyp Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Nasal and paranasal polyposis based Sino-Nasal Outcome Test (SNOT-22) scores to measure impact on symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>furosemide</description>
    <arm_group_label>Furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic rhinosinusitis and sinonasal polyposis who are candidates for
             functional endoscopic sinus surgery

        Exclusion Criteria:

          -  Hypersensitivity to furosemide or sulfonamides

          -  pregnancy

          -  history of tinnitus

          -  history of sensorineural hearing loss

          -  poorly controlled diabetes

          -  current diuretic therapy

          -  known electrolyte disorder

          -  currently taking aminoglycosides

          -  BUN and creatinine levels out of the normal range

          -  history of renal disease

          -  allergy to sulfonamides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beth Duddy</last_name>
    <phone>215-955-9880</phone>
    <email>elizabeth.duddy@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Department of Otolaryngology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Duddy, RN, BSN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

